Single-cell RNA sequencing sheds light on stroke-induced brain damage

Mor­phoSys is de­clar­ing suc­cess on a Phase III study in­volv­ing the key can­cer drug from its $1.7 bil­lion buy­out of Con­stel­la­tion, but a sec­ondary end­point

Share this article According to GlobalData’s company profile on Angelini, Peptide pharmacophores was a key innovation area identified from patents. Angelini’s grant share as of